Medication-Overuse Headache (Investigational Adjunct)
Investigational adjunct during withdrawal phase of medication-overuse headache; supervised medication discontinuation and preventive therapy initiation remain the foundation.
Patient Summary
- Is this FDA-cleared for this use?
- Not FDA-cleared for medication overuse headache. FDA cleared medicinal leeches only for venous congestion in microsurgical reconstruction (K040187, June 2004). Use for medication overuse headache is investigational.
- What evidence exists?
- Tier C (investigational). Only anecdotal reports; there are no randomized controlled trials. Evidence-based management of medication overuse headache: discontinuation of overused acute medications (gradual or abrupt depending on agent), initiation of preventive therapy (topiramate, propranolol, amitriptyline, CGRP monoclonal antibodies, onabotulinumtoxinA for chronic migraine), and patient education. Most patients improve significantly within 8 weeks of withdrawal with appropriate support.
- Main risks
- Bleeding from bite sites for 6 to 24 hours after detachment
- Trigger of withdrawal headache or rebound migraine
- Local skin infection or, rarely, Aeromonas infection
- Allergic reaction to leech saliva (uncommon)
- Worsening headache after the procedure
- Substitution for the essential step of discontinuing overused medication
- Delay of preventive therapy (topiramate, propranolol, CGRP monoclonal antibodies, onabotulinumtoxinA)
- Risk of missed secondary headache cause (intracranial hypertension, cerebral venous thrombosis)
- Who should not consider this
- Patients who have not yet discontinued their overused acute medication
- Patients without a neurology evaluation for secondary causes
- Patients on barbiturate or opioid overuse (requires inpatient withdrawal in some cases)
- Patients on anticoagulants, with hemophilia, or with severe anemia
- Pregnant patients
- Patients who have not been offered preventive therapy
- What to ask your clinician
- Have I been evaluated by a neurologist for medication overuse headache?
- Have I begun the process of discontinuing overused acute medications?
- Have I been offered preventive therapy (topiramate, propranolol, amitriptyline, CGRP mAb)?
- Am I a candidate for onabotulinumtoxinA (chronic migraine indication)?
- Has a secondary headache cause been ruled out (MRI, lumbar puncture if indicated)?
- What evidence specifically supports leech therapy for medication overuse headache?
- What is the cost and is it covered by insurance? (typically not covered)
- When to seek urgent care
- Sudden severe headache (worst of life — rule out subarachnoid hemorrhage)
- New weakness, numbness, slurred speech, or vision loss (possible stroke)
- Headache with fever and neck stiffness (possible meningitis)
- Headache with vision changes or papilledema (possible intracranial hypertension)
- Spreading redness, warmth, pus, or red streaks (cellulitis)
- Fever above 38.0 C / 100.4 F or chills
- Bleeding from a bite site lasting more than 24 hours
- Hives, facial or tongue swelling, throat tightness, or breathing difficulty
What this does NOT mean
- This is NOT FDA-cleared for medication overuse headache.
- Anecdotal reports do NOT establish efficacy versus medication withdrawal plus preventive therapy.
- It does NOT substitute for the essential step of discontinuing overused acute medications.
- It does NOT replace neurologic evaluation for secondary headache causes.
- It does NOT address the underlying chronic primary headache disorder driving overuse.
Safety cross-references
Clinical Profile
- Category
- neurological
- ICD-10
- G44.41, G44.40
- Safety tier
- medium
Evidence Summary
Medication-overuse headache (MOH) is daily or near-daily headache in patients with primary headache disorders who overuse acute treatments (triptans, ergots, opioids, butalbital combinations, simple analgesics). Evidence-based management is supervised discontinuation of the overused medication with management of withdrawal symptoms, initiation of preventive therapy (topiramate, beta-blockers, anti-CGRP monoclonal antibodies, or onabotulinumtoxinA for chronic migraine), and education to prevent recurrence. Bridge therapies during withdrawal include corticosteroid tapers and non-steroidal anti-inflammatory medications (when those are not the overused agent). No published controlled trials of hirudotherapy exist for MOH. Anecdotal occipital application is described in central European practice as withdrawal-period symptom support without disease-modifying mechanism.
Treatment specifics
How many leeches, where they are placed, how long a session lasts, and whether to repeat are clinical decisions made by a qualified provider under institutional protocol — not something to self-administer. Discuss the specifics with a clinician experienced in medicinal leech therapy. (Clinicians: switch the audience selector in the top bar to “Clinician” to view protocol detail.)
Contraindications
- Active anticoagulant therapy (warfarin INR >2.0, DOACs, heparin)
- Hemophilia or other bleeding disorder
- Severe anemia (Hb <10 g/dL)
- Active bacteremia or sepsis
- Known hypersensitivity to leech salivary proteins
- Pregnancy (relative — first/third trimester)
- Immunocompromised state with severe neutropenia
- Patient not under headache-specialist or neurology supervision
- Concurrent opioid or butalbital overuse without supervised taper plan
- Secondary headache not worked up (tumor, vascular, infection)
- Pregnancy (relative)
- Lateral neck placement near carotid
Related Conditions
Cervical Radiculopathy
Off-label use with one RCT (Michalsen 2018) showing significant pain reduction at 7 days in cervical radiculopathy without surgical indication.
Lumbar Radiculopathy (Sciatica)
Off-label use with controlled trial evidence (n=80) showing leg pain and Oswestry score improvement at 4-12 weeks in non-surgical lumbar disc disease.
Migraine
Investigational use with case-series evidence for reduction of migraine frequency and intensity; mechanism plausible via reduction of cervico-cranial venous congestion.
Tension-Type Headache
Investigational use with small case series suggesting frequency reduction in chronic tension headache via reduction of pericranial muscle tension and venous congestion.